Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Pyoderma Gangrenosum

abstract

  • Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF alpha), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

publication date

  • May 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1525-1470.2005.22320.x

PubMed ID

  • 15916580

Additional Document Info

start page

  • 262

end page

  • 5

volume

  • 22

number

  • 3